The new vaccine platform, described in a study published today in the journal _Science_, uses messenger RNA (mRNA) to deliver instructions to cells for making specific proteins. mRNA is a molecule that carries genetic information from DNA to the protein-making machinery in cells.
Traditional vaccines work by injecting a weakened or inactivated form of a virus or bacteria into the body, which triggers the immune system to produce antibodies against the pathogen. However, mRNA vaccines offer several advantages over traditional vaccines. They are faster to produce, can be more easily modified to target different diseases, and do not require the use of live or attenuated viruses.
In the new study, the researchers used mRNA vaccines to target three different diseases: Ebola, influenza, and _Toxoplasma gondii_. They found that the vaccines were able to induce strong immune responses in mice, and that the animals were protected from subsequent infection with the respective pathogens.
One of the key advantages of mRNA vaccines is their flexibility. The researchers were able to rapidly design and produce mRNA vaccines against each of the three diseases simply by changing the genetic code of the mRNA. This could allow for the rapid development of vaccines in response to new or emerging diseases, or to provide personalized vaccines tailored to individual patients.
"The simplicity and versatility of mRNA vaccines make them a promising platform for future vaccine development," said study leader Nicholas Pardi, a professor of bioengineering at UC Berkeley. "We believe that this technology could be used to develop vaccines against a wide range of infectious diseases, including some that have proven difficult to target with traditional vaccines."
The researchers are now planning to conduct clinical trials of their mRNA vaccines in humans. If the trials are successful, the new vaccines could be available to the public within a few years.
